FDA reportedly looking to fast-track Omicron vaccines and therapeutics
Variant has sent the world scrambling to reimpose lockdowns and mitigation measures.
The Facts Inside Our Reporter’s Notebook
The U.S. Food and Drug Administration is reportedly moving to fast-track new vaccines and drugs meant to target the recently emerged "Omicron" variant of the SARS-Cov-2 virus.
The drug agency "has been meeting with drugmakers and setting guidelines for the studies and data needed to swiftly evaluate products targeting the new Omicron Covid-19 variant," sources told the Wall Street Journal this week.
The approval process for any new vaccines will reportedly be subject to the same requirements as those of the recently deployed COVID-19 boosters, the paper reported.
The Omicron variant was first detected in Africa last month, touching off a flurry of travel bans and lockdowns around the world, though at least one of the doctors who helped discover the variant has described that the symptoms associated with the variant as "extremely mild."
Just News, No Noise
- New twist in FBI raid: Trump had 'standing order' to declassify documents taken to residence
- Whistleblowers revealed widespread FBI misconduct ahead of Trump raid
- Poll: Soaring number of Americans say they’re getting back to ‘normal, pre-COVID’ life
- MSNBC contributor, ex-spy chief hint Trump deserves execution over classified records dispute
- Air Force pushing religious objectors to get vax that used human fetal cells, military lawyer claims